Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | OGT | O15294 | 8/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17406934 | 0.90 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2AOGTPKM | |
| SCHEMBL17406948 | 0.89 | OGT (0.51) | ALDH1A1MEN1KMT2AOGTPKM | |
| SCHEMBL2633965 | 0.89 | OGT (0.51) | ALDH1A1MEN1KMT2AOGTPKM | |
| SCHEMBL4544668 | 0.86 | OGT (0.66) | ALDH1A1MEN1KMT2AOGTPKM | |
| SCHEMBL18965264 | 0.86 | OGT (0.66) | ALDH1A1MEN1KMT2AOGTPKM | |
| SCHEMBL17406957 | 0.86 | OGT (0.66) | ALDH1A1MEN1KMT2AOGTPKM | |
| SCHEMBL4544659 | 0.85 | OGT (0.67) | ALDH1A1MEN1KMT2AOGTPKM | |
| SCHEMBL4544734 | 0.85 | OGT (0.49) | ALDH1A1MEN1KMT2AOGTPKM | |
| SCHEMBL4544651 | 0.85 | OGT (0.66) | ALDH1A1MEN1KMT2AOGTPKM | |
| SCHEMBL18965303 | 0.85 | OGT (0.66) | ALDH1A1MEN1KMT2AOGTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2016004180-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166558-A1 | O-GLCNAC TRANSFERASE (OGT) INHIBITORS AND USES THEREOF | OGA, OGT, CSGALNACT1 | ALDH1A1 995/4885MEN1 3624/4885KMT2A 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.